Mz1 - OmicsDI

Show results for

Genomics (30)
Unknown (28)
Transcriptomics (11)
Proteomics (9)
Metabolomics (1)

Organisms

Homo sapiens (16)
Alphavirus (8)
Anemia (8)
Archaea (8)
Bacteria (8)
Betaherpesvirinae (8)
Borrelia (8)
Chlamydomonas reinhardtii (8)
Chlorella vulgaris (8)
Clostridium perfringens (8)
Dengue virus (8)
Eukaryota (8)
Hepatitis B virus (8)
Human alphaherpesvirus 1 (8)
Human betaherpesvirus 5 (8)
Influenza A virus (8)
Influenza C virus (8)
Japanese encephalitis virus group (8)
Kamptonema sp. (8)
Listeria monocytogenes (8)
Mammarenavirus (8)
Miscanthus x giganteus (8)
Mycobacterium tuberculosis (8)
Orthoflavivirus (8)
Pseudomonas aeruginosa (8)
Rattus (8)
Sarbecovirus (8)
Severe acute respiratory syndrome coronavirus 2 (8)
Staphylococcus aureus (8)
Drosophila melanogaster (1)

Organisms

Homo sapiens (18)
Staphylococcus sp. MZ1 (1)
Aurantimicrobium sp. Mo1 (1)
Drosophila melanogaster (1)

Repository

ENA (25)
geo (16)
pride (8)
jPOST (1)
MetaboLights (1)

Tissue

Cell culture (3)
Epithelial cell (1)
Permanent cell line cell (1)
Prokaryotic cell (1)

Disease

Rickettsialpox (1)

Technology Type

Mass Spectrometry (8)
Bottom-up proteomics (4)
Data-dependent acquisition (4)
Data-independent acquisition (4)
Gel-based experiment (4)
Mass spectrometry (1)
Chemical cross-linking coupled with mass spectrometry proteomics (1)

Instrument Platform

Liquid Chromatography MS - positive - reverse phase (1)

CHEBI ID

CHEBI:189652 (1)

Metabolite Name

Mz1 (1)

First Public Date

2023 (7)
2024 (4)
2026 (3)
2022 (3)
2020 (3)
2025 (2)
2021 (2)
2018 (1)

Release Date

2021 (6)
2020 (4)
2019 (4)
2025 (3)
2023 (3)
2026 (2)
2024 (2)
2022 (2)
2018 (1)
2017 (1)

Lab affiliation

University of Dundee, Scool of Life Sciences, Department of Molecular, Cellular andDevelopmental biology (2)
Department of Life Technologies and InFLAMES Research Flagship, University of Turku, FI-20014, Turku, Finland (1)
Head of proteomic facility, Institute of Virology, BMC, Slovak Academy of Sciences, Bratislava, Slovak Republic (1)
Medicinal Chemistry, Monash Institute of Pharmaceutica Science, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia (1)
OmicScouts GmbH, Freising, Germany (1)
Professor Alessio Ciulli Director Centre for Targeted Protein Degradation 1 James Lindsay Place Dundee DD1 5JJ (1)
University of Dundee, School of Life Sciences, Department of molecular, cellular and developmental biology (1)

Publication date

2025 (8)
2023 (6)
2026 (4)
2024 (4)
2022 (2)
2021 (2)

Previous page
1 / 8
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 8
Next page

Sort by:

Relevance

Page size

The efflux pump ABCC1/MRP1 constitutively restricts PROTAC sensitivity in cancer cells

Proteolysis targeting chimeras (PROTACs) are bifunctional molecules that induce selective protein degradation by linking an E3 ubiquitin ligase enzyme to a target protein. This approach allows scope for targeting “undruggable” proteins and several PROTACs have reached the stage of clinical candidate...

2025-07-17 | MTBLS11394 | MetaboLights

Staphylococcus sp. MZ1

Staphylococcus sp. MZ1 Genome sequencing

PRJNA730223 | ENA

BRD4 inhibitor MZ1 exerts anti-cancer effects in Neuroblastoma

PRJNA797669 | ENA

Transcriptome profiles of lymphoma cell lines after treatment with MZ1 compunds

PRJNA641082 | ENA

BRD4 inhibitor MZ1 exerts anti-cancer effects in Neuroblastoma

MZ1 is a newly designed pan-BET-targeting PROTAC that binds to target proteins (BET proteins such as BRD2, BRD3, and BRD4) and recruits them to the ubiquitin/protease pathway for selective destruction. However, the role of MZ1 in NB models has yet to be determined. The effect of MZ1 on NB cells was ...

ORGANISM(S): Homo sapiens

2022-08-29 | GSE193767 | GEO

MZ1 co-operates with trastuzumab in HER2 positive breast cancer.

Not available

S-EPMC7980639 | biostudies-literature

MZ1, a BRD4 inhibitor, exerted its anti-cancer effects by suppressing SDC1 in glioblastoma.

Not available

S-EPMC10870565 | biostudies-literature

RNA-seq for NB4 cell line in either the absence or presence of MZ1

PRJNA813400 | ENA

BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes.

Not available